

# Astigmatism and maternal myopia as important factors affecting success rate of DIMS lens treatment

Patricia Domsa,<sup>1,2</sup> Éva M Bankó ,<sup>3</sup> Judit Körtvélyes,<sup>1,4</sup> Christof Meigen,<sup>5</sup> Rita Szécheý,<sup>1,6</sup> Krisztina Lantos,<sup>2</sup> Zoltán Zsolt Nagy,<sup>7</sup> Adrienne Csutak<sup>2</sup>

**To cite:** Domsa P, Bankó ÉM, Körtvélyes J, *et al*. Astigmatism and maternal myopia as important factors affecting success rate of DIMS lens treatment. *BMJ Open Ophthalmology* 2024;**9**:e001499. doi:10.1136/bmjophth-2023-001499

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjophth-2023-001499>).

PD and ÉMB are joint first authors.

ZZN and AC are joint senior authors.

Received 17 September 2023  
Accepted 28 January 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Éva M Bankó; [banko.eva@ttk.hu](mailto:banko.eva@ttk.hu)

## ABSTRACT

**Objective** To assess the efficacy of myopia control spectacle lenses (defocus incorporated multiple segments/ DIMS) in slowing myopia progression among a diverse Central European paediatric population and investigate the contribution of baseline parameters on treatment outcomes.

**Methods and analysis** This retrospective observational study included 62 individuals aged 4–17 years (mean±SD: 10.21±2.70) with progressing myopia but without ocular pathology with a range of −0.88 to −8.25 D spherical equivalent refraction (SER) (−3.73±1.56), coupled with astigmatism up to −3.25 D cylindrical. All participants were prescribed DIMS (Hoya MiyoSmart) spectacles. Key outcome variables were cycloplegic SER, measured for all participants and axial length (AL), assessed in a subset of patients, recorded at baseline, 6 months and 12 months. Quality of life assessments were conducted at baseline, at 2 weeks, and 3, 6, 9 and 12 months. Additionally, parental myopic dioptre was recorded when applicable.

**Results** At the 12-month mark, myopia progression in patients (mean±SE: −0.40±0.05) mirrored findings from prior European DIMS studies, but with 50% of patients showing no progression. A multivariate analysis of covariance model revealed that baseline astigmatism and younger age adversely affected therapy outcomes in both SER and AL, while severe maternal myopia led to greater SER progression. In contrast, only young age but not astigmatism was associated with AL increase in a comparable group of children with myopia, part of the LIFE Child Study, wearing single-vision spectacles. Patients reported consistent satisfaction with treatment, with minimal side effects, which diminished over the year.

**Conclusion** In the European population, astigmatism, young age and severe maternal myopia are risk factors for suboptimal outcomes following DIMS therapy. Further research is necessary to elucidate the impact of astigmatism on myopic defocus therapy.

## INTRODUCTION

Myopia has witnessed a rapid increase in prevalence in recent years becoming a global public health concern. Over 30% of Europeans are affected by myopia,<sup>1</sup> with numbers surpassing 40% among school-age children<sup>2</sup> contributing to a significant vision concern within the region. Current estimated prevalence is

### WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Spectacle lenses with ‘defocus incorporated multiple segments’ (DIMS) technology reduce myopia progression in European population, and this effect is dependent on patients’ age.

### WHAT THIS STUDY ADDS

⇒ Efficacy of DIMS lenses is negatively affected by the presence of astigmatism and high maternal myopia.  
⇒ DIMS technology, a minimally invasive therapy to slow down myopia progression, has barely negative consequences in quality of life throughout the entire treatment even at a young age.

### HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Further research into DIMS therapy should consider the degree and angle of astigmatism of patients when evaluating treatment outcome.  
⇒ For patients with astigmatism and/or severe maternal myopia, combination therapy should be considered, such as DIMS technology and low-dose atropine, especially at a young age.  
⇒ As the technology is well tolerated and effective over a wide dioptric range, it can be used in patients with high myopia.

slightly higher in Western Europe (36.7%), compared with Eastern Europe (32.2%).<sup>3</sup> Nevertheless, based on the representative nationwide screening programme conducted on adults in the past 10 years, myopia prevalence is 43.45% in Hungary, and it is three times more frequent in younger people (58.7%; 18–35 years) compared with older age groups (19.4%; 56–70 years).<sup>4</sup> This is in stark contrast with data from the first half of the 20th century, when myopia prevalence was well under 10% among schoolchildren in Budapest.<sup>4</sup> Globally, myopia’s prevalence is surging, with projections suggesting that by 2050, nearly half of the world’s population could be impacted by this refractive error, with estimates of 65%, 56%, 54% and 50% in Asia, Western, Central and Eastern Europe, respectively, if serious countermeasures are



not taken.<sup>3</sup> Myopia's development is influenced by a complex interplay of genetic and environmental factors. Prolonged near work, limited outdoor time, education level, family history of myopia and certain ethnic backgrounds are key risk factors associated with its onset and progression.<sup>5,6</sup> High myopia, characterised by a spherical equivalent of  $-6.0$  D or worse, carries substantial ocular risks. These include myopic maculopathy, retinal detachment and glaucoma, leading to severe visual impairment and potential blindness.<sup>7,8</sup>

Researchers and practitioners have been exploring innovative ways to control myopia progression. Several widely tried therapeutic approaches, including under-correction,<sup>9–13</sup> pinhole glasses, blue light blocking glasses, bifocal glasses,<sup>14,15</sup> progressive addition spectacle lenses,<sup>16–21</sup> daytime single-vision soft contact lenses/rigid gas permeable contact lenses<sup>22–27</sup> and others, have demonstrated limited effectiveness in significantly retarding the progression of myopia. Research suggests that these interventions often fail to address the underlying mechanisms driving myopia's development and may provide only minimal benefits in controlling its advancement. Promisingly, effective myopia control strategies encompass a range of interventions, including increased outdoor time,<sup>28–34</sup> reduced engagement with smartphones and near tasks,<sup>35–38</sup> as well as the utilisation of advanced technologies like DIMS (defocus incorporated multiple segments) lenses,<sup>39–44</sup> highly aspheric lenslet lenses,<sup>45–47</sup> soft multifocal contact lenses,<sup>44,48–54</sup> orthokeratology<sup>55–59</sup> and low-dose atropine eye drops.<sup>60–67</sup> These approaches have demonstrated the potential to counter myopia progression by addressing various contributing factors and are paving the way for a more proactive approach to visual health management.<sup>68</sup>

One such ground-breaking approach is the use of spectacle lenses with DIMS technology; DIMS technology operates by integrating a central optical zone for correcting distance vision and an annulus of tiny circular segments with a relative positive power of  $3.50$  D distributed across the mid-peripheral area, each  $\sim 1$  mm in diameter, in a honeycomb pattern.<sup>39,44,69,70</sup> This arrangement induces peripheral myopic defocus while maintaining clear vision, harnessing the principles of peripheral defocus and simultaneous vision to curtail axial elongation and mitigate myopia progression. Notably, these lenses offer a minimally invasive solution, making them a promising avenue for managing myopia while prioritising patients' well-being.<sup>43,71</sup>

Although most of the available data concern Asian populations, a recent study has reported a significant efficacy rate of approximately 50–60% in reducing myopia progression among European populations using DIMS lenses.<sup>72</sup> Moreover, Truckenbrod *et al*<sup>73</sup> presented data indicating a parallel pattern of axial length (AL) growth between the Asian and European populations, and research on the adaptation and acceptance of DIMS among Chinese children contributed valuable insights, that apart from slightly affected mid-peripheral vision,

DIMS lenses received good tolerance and acceptance by Chinese children.<sup>43</sup>

Even though there is a growing body of evidence of the effectiveness of DIMS lenses, the existing studies, except one,<sup>74</sup> have limited inclusion to moderate myopia with also a limit on the maximum allowed astigmatism. Our study, therefore, was aimed to assess the effectiveness of DIMS lenses in attenuating myopia progression within a European paediatric cohort, encompassing a diverse dioptre range from  $-0.88$  spherical equivalent refraction (SER) to  $-8.25$  SER with special focus on investigating the impact of baseline optic parameters as well as parental myopia on the efficacy of DIMS lenses. Additionally, we endeavoured to demonstrate the broad age range tolerance of DIMS lenses, spanning from 4 to 17 years. Our results highlight the significance of tailored strategies for children with familial predisposition and astigmatism as risk factors for therapeutic failure and underline adaptability of DIMS therapy across diverse paediatric age groups and a wide range of dioptres.

## MATERIALS AND METHODS

### Study design

The study was a retrospective observational study with data collection carried out in a paediatric ophthalmology private practice setting in Budapest that has a reputation of offering state-of-the-art treatment including DIMS therapy. Due to the existing robust evidence supporting the technology's effectiveness, DIMS lenses (Hoya MiyoSmart, Tokyo, Japan) were offered to children with evolutive<sup>75</sup> myopia who had exhibited myopia progression in the preceding year ( $\geq 0.5$  DSPH (spherical dioptre)/year). Thus, a comparable control group of evolutive myopes treated with single-vision spectacles was not available, and seems ethically unfeasible in light of previous results. Nevertheless, we included the analysis of AL data from a myopic subset of a larger cohort of German children participating in the LIFE Child Study.<sup>73</sup> Patients who had completed the first year of their DIMS therapy since 2021 with no data gaps were included in the study with cycloplegic autorefractometry SER and AL as key outcome measures, which were assessed at baseline, 6 months (SER only) and culminating at the 12-month mark. The median time between baseline and 6-month and baseline and 12-month visits was 210 and 386 days, respectively. In addition to clinical assessments, participants completed a quality of life (QoL) questionnaire at baseline and after 2 weeks, 3, 6, 9 and 12 months, the baseline measurements relating to the previous single-vision spectacles of the patients. For reporting, the Strengthening the Reporting of Observational Studies in Epidemiology guidelines were used.<sup>76</sup>

### Participants

The study encompassed a cohort of 62 participants, comprising of ethnic Caucasians of Hungarian descent, ranging in age from 4 to 17 years (mean $\pm$ SD: 10.21 $\pm$ 2.70 years; 37 females [table 1]). Myopia was

**Table 1** Patient baseline characteristics; N=62, where not indicated otherwise

Age at enrolment (years)	10.21±2.70 (4–17)		
Gender			
Male, % (n)	40 (25)		
Female, % (n)	60 (37)		
Cycloplegic autorefraction	<b>SER (D)</b>	<b>SPH (D)</b>	<b>CYL (D)</b>
Right eye	−3.76±1.59 (−7.75 to −0.88)	−3.46±1.55 (−0.75 to −7.25)	−0.62±0.45 (−2.75 to 0)
Left eye	−3.70±1.63 (−8.75 to −0.63)	−3.38±1.58 (−0.5 to −8.0)	−0.64±0.61 (−3.75 to 0)
Average	−3.73±1.56 (−8.25 to −0.88)	−3.42±1.51 (−7.63 to −0.75)	−0.63±0.49 (−3.25 to −0.13)
Axial length (mm) (n=33)			
Right eye	24.53±0.95 (22.66–26.47)		
Left eye	24.49±0.97 (22.65–26.41)		
Average	24.51±0.96 (22.66–26.39)		
Myopic parents' D			
Maternal	−2.90±3.19 (0 to −13)		
Paternal	−1.09±1.92 (0 to −10.5)		

Values indicate mean±SD and (min–max).

CYL, cylindrical; D, dioptre; SER, spherical equivalent refraction; SPH, spherical.

defined as SE  $\leq -0.5$  D and participants exhibited myopia within the range of  $-0.875$  to  $-8.75$  D SER ( $-3.73 \pm 1.56$  SER), coupled with astigmatism up to  $-3.25$  DCYL (cylindrical dioptre). Inclusion criterion was  $-0.5$  DSPH or more progression in the year before DIMS therapy, while exclusion criteria included any significant ophthalmic pathology other than myopia and refractive errors exceeding  $-10.0$  SPH or  $+4.0$  CYL due to the limitations of the DIMS technology, which is not available for use beyond these dioptres.

### Intervention

DIMS spectacles (Hoya MiyoSmart, Tokyo, Japan) were prescribed for all participants and they were instructed to wear them to waking hours replacing their single-vision spectacles. Participants were informed of the potential side effects and were asked to periodically fill out a QoL questionnaire related to DIMS.

### Procedures

Clinical measurements included best-corrected visual acuity, autorefraction (Topcon KR-800, Tokyo, Japan) conducted in cycloplegia (achieved through two drops of 10 mg/mL (1%) cyclopentolate (Laboratório Edol Produtos Farmacéuticos, Portugal), with the second administered at 15 min and refractometry conducted 25 min after the second drop), as well as AL measurements (Topcon Myah, Visia Imaging, Italy) on a subgroup of patients (N=33). Furthermore, a dilated funduscopy was performed for every patient (SM-70N, Takagi Seico Co, Tokyo, Japan) with a Volk digital wide-field lens (Volk Optical, Mentor, Ohio, USA). To investigate the influence of parental myopia, anamnestic data on familial myopic history were collected with exact dioptre values gathered

from information on prescription glasses. For parents without myopia, zeros were entered instead. The QoL questionnaire was obtained from Hoya and included 14 questions with answers on a five-level Likert scale: the first half relating to symptoms experienced during wear, the second half relating to patient satisfaction.

### Single-vision control group

For comparison, we used data from a myopic subset (N=187) of a larger cohort of German children participating in the LIFE Children Study,<sup>73</sup> where AL was measured and followed longitudinally. Since that dataset only had non-cycloplegic refractive data, only the AL outcome measure is analysed here. Age range and exclusion criteria were identical to our DIMS group for better comparison. However, no information was present on their myopic progression before enrolling in the study. For procedures, please refer to the original article. Their baseline optical parameters are detailed in table 2.

### Statistical analysis

To describe overall progression, mean and SE were used for both SER (N=62) and AL (N=33). No progression was defined as both eyes having less than  $-0.5$  SER D change at the end of the 1-year follow-up.<sup>77</sup> As no difference was found between eyes either in baseline characteristics or progression (paired t-test: all  $t \leq 0.34$ ,  $p \geq 0.23$ ), we averaged all measured and calculated values across eyes to increase the signal-to-noise ratio. Normality assumptions were tested with one-sample Kolmogorov-Smirnov tests. A general linear mixed model (GLMM) was used for modelling treatment outcome to estimate the effect of baseline parameters. To do so, post-intervention results were calculated as change from baseline (CFB)—calculated

**Table 2** Baseline characteristics of a myopic subset of the LIFE Child Study dataset, N=187

Age at enrolment (years)	13.26±3.13	
Gender		
Male, % (n)	51 (96)	
Female, % (n)	49 (91)	
Non-cycloplegic autorefraction	<b>SPH (D)</b>	<b>CYL (D)</b>
Right eye	-1.76±1.39	-0.56±0.48
Left eye	-1.71±1.36	-0.57±0.47
Average	-1.74±1.32	-0.57±0.47
Axial length (mm)		
Right eye	23.91±1.04	
Left eye	23.98±1.02	
Average	23.90±1.02	
Maternal		
Myopic, % (n)	64 (120)	
Non-myopic, % (n)	36 (67)	
Values indicate mean±SD. CYL, cylindrical; D, dioptre; SER, spherical equivalent refraction; SPH, spherical.		


as post/pre-values—for both the 6-month ( $CFB_{6m}$ ) and the 12-month ( $CFB_{12m}$ ) visits and were used as dependent variables, with ‘time’ as a within-subject factor. Additional predictors included ‘age’, ‘baseline SER’ (in the case of SER analysis) and ‘baseline AL’ (in the case of AL analysis), ‘maternal myopic dioptre’ and ‘paternal myopic dioptre’ as covariates, and ‘presence of astigmatism’ as a between-subject factor. The model included an interaction term between ‘time’ and each predictor/covariate. For data obtained from the German LIFE Child Study dataset, data were available for AL measurements and only the myopic status of the mother was noted. Therefore, the GLMM used here had  $CFB_{12m}$  as dependent variable, with ‘age’ and ‘baseline AL’ as covariates, and ‘maternal myopic status’ and ‘presence of astigmatism’ as between-subject factors. Patients were categorised as astigmatic if either eye had a larger than  $-0.5$  DCYL at baseline (N=38 out of 62). For understanding age-related effects, patients were assigned into two separate age groups (<10 years and  $\geq 10$  years, N=26 and N=36, respectively) and a similar GLMM was conducted, and Tukey HSD tests were used for post-hoc comparison. Significant effects concerning covariates were tested with Pearson correlation or partial correlation analysis, while the relationship between the presence of astigmatism and progression was tested with Pearson  $\chi^2$  test. Possible differences between the distributions of maternal and paternal myopic dioptres were evaluated by a two-sample Kolmogorov-Smirnov test. Statistical analyses were run using Statistica V.14 (TIBCO Software, Palo Alto, California, USA) and R code using R Studio (Posit Software, PBC, Boston, Massachusetts, USA).

## RESULTS

### Changes in spherical equivalent

Baseline characteristics of the study population can be found in table 1. The mean ( $\pm$ SE) unadjusted myopia progression (SER) over the 1-year period for the whole study group (N=62) was  $-0.40\pm 0.05$  D, with 31 (50%) patients showing no progression at the end of the 1-year period (figure 1A). To investigate the possible contribution of clinical factors to the individual variation in myopia progression, an analysis of covariance approach was adopted, where both  $CFB_{6m}$  and  $CFB_{12m}$  were included as dependent variables. We examined age, baseline and familial optical parameters, namely baseline SER, the presence or lack of clinically significant astigmatism (ie, type of myopia) at baseline, and parental myopia (maternal and paternal myopic dioptre) and their interaction with time to determine their effect on therapy outcome, that is, the SER change from baseline. As expected, time had the most pronounced effect on progression ( $F_{(1,56)}=24.92$ ,  $p<0.0001$ ), as patients showing progression despite DIMS treatment progressed even further from the 6-month to 12-month visit. Patients’ age did not have a significant main effect on progression ( $F_{(1,56)}=3.24$ ,  $p=0.077$ ) but significantly interacted with time ( $F_{(1,56)}=12.44$ ,  $p=0.0008$ ). Thus, patients of different ages had different patterns in their progression dynamics. Pearson correlations revealed that while there was no age-specific progression at 6 months ( $CFB_{6m}$  vs age:  $r_{(60)}=0.18$ ,  $p=0.17$ ), correlations between further progression and age ( $CFB_{12m}-CFB_{6m}$  vs age:  $r_{(60)}=0.42$ ,  $p=0.001$ ), and 12-month progression and age ( $CFB_{12m}$  vs age:  $r_{(60)}=0.37$ ,  $p=0.003$ ) were significant. This was due to the fact that while older ( $\geq 10$  years) patients’ progression slowed down after 6 months, younger patients progressed further at a similar rate achieving significantly larger progression at 12 months (figure 1B, age group $\times$ time:  $F_{(1,56)}=14.53$ ,  $p=0.0003$ , post-hoc  $p=0.0004$  for  $CFB_{12m\_YOUNG}$  vs  $CFB_{12m\_OLDER}$ ). There was also no effect of baseline SER D (main effect:  $F_{(1,56)}=0.001$ ,  $p=0.97$ ; interaction with time  $F_{(1,56)}=0.04$ ,  $p=0.85$ ), indicating a similar efficacy profile of DIMS lenses for high as for moderate myopia.

Importantly, progression was also significantly affected by the presence of astigmatism ( $F_{(1,56)}=5.20$ ,  $p=0.026$ ) with the astigmatic group displaying significantly greater overall progression compared with the purely axial myopic group (figure 1C,  $-0.49\pm 0.07$  SER vs  $-0.26\pm 0.07$  SER for patients with astigmatic and purely axial-type myopia at 12 months, respectively). This pattern was present throughout the study (time $\times$ astigmatism  $F_{(1,56)}=1.54$ ,  $p=0.22$ ). When assessing the presence of astigmatism in the non-progressing group of patients, there was a significant relationship between the presence of astigmatism and progression in SER ( $\chi^2=9.79$ ,  $p=0.0018$ ; 81% vs 41% of patients were astigmatic in the progressing vs non-progressing groups, respectively). The same pattern was found when analysing  $CFB_{12m}$  refractive data transformed into Long’s matrix of (f11 f12 f22)<sup>78–80</sup> using an analogous model (online supplemental table 1; main




**Figure 1** Model-adjusted mean progression in SER from baseline to 12 months. (A) Group progression (N=62). (B) Different progression dynamics of patients <10 years and  $\geq 10$  years old. Younger patients show faster progression, which does not taper off after 6 months. (C) Different progression rates between patients with astigmatism and those with axial myopia, the former showing significantly greater progression. (D) 12-month change as a function of maternal myopia. Only patients with mothers with severe ( $\geq 9$  D) myopia show markedly larger progression. The values are least-squares estimates with continuous predictors as age, baseline dioptre, maternal and paternal dioptres fixed at their mean. Error bars indicate  $\pm$ SE. SER, spherical equivalent refraction.

effect of astigmatism:  $F_{(1,54)}=4.45$ ,  $p=0.039$ ; mean change  $-0.37/-0.22 \times 79$  vs  $-0.23/-0.04 \times 142$  for patients with and without astigmatism, respectively). Interestingly, the change in the f12 component, which is computed from the DCYL and its respective axis, showed virtually no difference between these patient groups (online supplemental figure 1). Therefore, it seems that the significant difference in SER change in patients with astigmatic and axial-type myopia comes from the different degree of change in spherical power, which could reflect the different rates of axial elongation between these groups.

Lastly, parental myopia also had a notable contribution to progression: maternal ( $F_{(1,56)}=3.90$ ,  $p=0.053$ ), but not paternal myopic dioptre ( $F_{(1,55)}=0.14$ ,  $p=0.71$ ), had a strong tendency to affect progression, with no significant interaction with time (all  $F \leq 1.01$ ,  $p \geq 0.32$ ). This pattern was driven by patients having a mother with severe myopia showing the most progression (figure 1D). The distinguished role of the mother—at least in our sample—is also supported by the finding that our pool of mothers displayed significantly higher myopia compared with that of the fathers (two-sample Kolmogorov-Smirnov test:  $D_{(62,62)}=-0.30$ ,  $p<0.01$ ;  $-2.90 \pm 0.41$  D vs  $-1.09 \pm 0.24$  D for mothers and fathers, respectively).

### Changes in AL

The mean unadjusted 12-month increase in AL in a subset of our study group (N=33), where AL was measured, was  $0.16 \pm 0.03$  mm (figure 2A). The extent of axial elongation was significantly dependent on patients' age ( $F_{(1,27)}=10.42$ ,  $p=0.003$ ), with younger patients showing more pronounced elongation, while the effect of parental myopia only showed a non-significant trend ( $F_{(1,27)}=3.32$ ,  $p=0.079$  and  $F_{(1,27)}=2.77$ ,  $p=0.11$  for maternal and paternal myopic dioptres, respectively). Baseline AL had no effect ( $F_{(1,27)}=0.021$ ,  $p=0.65$ ). Notably, the presence of astigmatism had a significant effect on axial elongation as well ( $F_{(1,27)}=4.73$ ,  $p=0.039$ ;  $0.20 \pm 0.05$  mm vs  $0.12 \pm 0.04$  mm for patients with and without astigmatism, respectively). Importantly, the analysis of a larger cohort of German children wearing single-vision spectacles yielded contrasting results. While the axial elongation was also dependent on patients' age ( $F_{(1,182)}=46.94$ ,  $p<0.0001$ ), with younger patients progressing at a larger rate, the presence of astigmatism had absolutely no effect on myopia progression ( $F_{(1,182)}=0.003$ ,  $p=0.96$ ;  $0.12 \pm 0.02$  mm vs  $0.11 \pm 0.01$  mm for patients with and without astigmatism, respectively). In addition, maternal myopia had also no effect on progression ( $F_{(1,182)}=0.54$ ,  $p=0.46$ ), as opposed to baseline AL,



**Figure 2** Group average and model-adjusted mean progression in axial length at 12 months split by age group and presence of astigmatism. (A) Data for children wearing DIMS lenses. The values are least-squares estimates with continuous predictors as age, baseline dioptre, maternal and paternal dioptres fixed at their mean (N=33). (B) Data for children wearing single-vision spectacles (N=187). Error bars indicate  $\pm$ SE. \*P<0.05, \*\*p<0.01. DIMS, defocus incorporated multiple segments.

which influenced AL elongation ( $F_{(1,182)}=9.17$ ,  $p=0.003$ ). These results obtained with single-vision children corroborate our findings that the efficacy of DIMS lenses in slowing down the myopia progression of patients with astigmatism seems to be less, compared with patients with axial-type myopia.

### QoL questionnaire


The results of the QoL questionnaire demonstrated an excellent long-term overall acceptance of the DIMS spectacles for both the entire group (figure 3A) and for the youngest patients aged 4–7 years (figure 3B). In addition, there was very low incidence of side effects (figure 3C), which were almost completely resolved after 12 months except for a few cases of occasional eye strain, which seemed to persist throughout the study. Importantly, the young age group showed a very similar pattern (figure 3D) demonstrating the usability of DIMS glasses even at a young age. Interestingly, DIMS spectacles scored somewhat higher in user satisfaction and lower in the incidence of side effects compared with patients' previous single-vision glasses, which also emphasises its clinical relevance.

### DISCUSSION

Our objective was to investigate the effectiveness of DIMS technology lenses within a more diverse paediatric population, building upon the established and promising literature. This endeavour aimed to deepen our understanding of the variables that might impact the success of this therapeutic approach. We have found that the presence of astigmatism in our group of patients with myopia resulted in larger progression compared with patients with purely axial myopia, potentially diminishing the effects of DIMS lenses in slowing myopia progression. In

addition, patients with severe maternal myopia also experienced a significantly more pronounced progression. Finally, younger age was associated with faster progression, which, unlike that of older children, did not slow down after 6 months, achieving larger progression at 12 months. These findings underline the importance of astigmatism, severe maternal myopia and young age as risk factors for myopia progression, even when using DIMS spectacles.

When comparing the mean progression of our patients with other published results, we found our results to be largely consistent with the 1-year results of Nucci *et al*<sup>72</sup> in a European population but higher than the  $-0.17$  D SER progression found by Lam *et al*<sup>69</sup> in an Asian population. While the impact of ethnic differences on myopia progression is somewhat controversial,<sup>73,81</sup> the difference may be attributed to the fact that both the current and the Nucci *et al* study predominantly included evolutive myopes who have shown myopia progression in the previous year, and larger astigmatism was allowed. Nevertheless, among our patients, 31 (50%) did not progress by the end of the 1-year period, defined by no dioptric deterioration exceeding  $-0.5$  D SER in any eye.<sup>77</sup> Taken together, the mean progression and per cent of non-progressing myopes also show close resemblance to the only available large-scale retrospective study conducted in real-world clinical settings.<sup>74</sup> It has been shown that both children and adults tolerate DIMS lenses well,<sup>43,69,82</sup> with minimal mid-peripheral visual acuity and contrast sensitivity reduction in nasal and temporal gaze. We assessed acceptance throughout the 1-year treatment and obtained similar results, with minimal habituation complaints in children wearing DIMS lenses, primarily in the initial period of wear. Young children exhibited a



**Figure 3** Results of the quality of life questionnaire. (A) Incidence of reported symptoms in the whole group (B) and in patients under 8 years old (N=8). (C) Patient satisfaction in the whole group (D) and in patients under 8 years old. Scales for rating ranged from 1 to 5 (never to always and poor to excellent, respectively). Error bars indicate  $\pm$ SE.

similar profile highlighting the clinical relevance of DIMS spectacles. Interestingly, DIMS lenses scored somewhat higher in user satisfaction and lower in the incidence of side effects compared with patients' previous single-vision glasses, indicating comparable usability with the standard of care.

Previous larger DIMS studies<sup>69 70 72</sup> tended to include participants with mild and moderate myopia not exceeding  $-5.0$  D (SER). Consequently, there are limited data on the efficacy of DIMS lenses on patients with high myopia. Verkicharla *et al*<sup>83</sup> found that 1-year myopia progression was dependent on initial dioptres in children with myopia wearing single-vision lenses, with the largest progression seen in severe myopes ( $>9$  D SER), followed by high, moderate and mild myopes, which is in line with findings of other studies.<sup>84 85</sup> However, studies evaluating the efficacy of DIMS lenses did not find a similar relationship between initial dioptres and progression rate, as including baseline SER as a covariate did not affect therapy outcomes.<sup>69 72</sup> Our results also support the idea that the initial dioptre value is not related to the degree of progression when using DIMS spectacles for myopia control, in line with the above findings. Therefore,

patients with high myopia can also benefit from this therapy.

It is well-known that curvatural myopes with a small AL form a well-defined group of patients with a low risk of progression,<sup>77</sup> and the effect of astigmatic defocus on the progression of myopia is an area of intense research.<sup>86-89</sup> Nevertheless, in myopes showing progression, the presence of astigmatism is somewhat overlooked, as the commonly used practice of calculating the spherical equivalent merges the contribution of spherical and cylinder dioptres. Our results suggest that the efficacy of DIMS lenses is higher in pure axial myopes without astigmatism ( $\leq -0.5$  DCYL), as mean progression (SER) was significantly lower in axial myopes, and there was a significant relationship between astigmatism and myopia progression: progressing myopes were twice more likely to have had astigmatism compared with non-progressing myopes. This group difference was reflected in spherical dioptre (f11 and f22 Long's matrix components of refractive power) and AL alterations, while no difference in the change in f12 component, reflecting only DCYL was observed between the two groups. Importantly, there was no difference in AL elongation between children with



axial and astigmatic myopia wearing single-vision spectacles. Indeed, the presence of astigmatism was also related to the lack of improvement in children with amblyopia as a result of augmented reality dichoptic training.<sup>90</sup> Moreover, imposing both spherical and cylindrical hyperopic defocus early in life was found to lead to differential changes in eye anatomy compared with purely spherical hyperopic defocus in chicks.<sup>86</sup> Myopic astigmatic defocus also had a significantly different impact on changes in choroidal thickness after short-term exposure compared with spherical myopic defocus in humans.<sup>89</sup> Our findings suggest that astigmatism is not an overall risk factor for progression. However, it may disrupt the uniformity of peripheral myopic defocus, potentially challenging the effectiveness of DIMS technology. Another possibility is that axial elongation and changes in corneal curvature are influenced by separate, interdependent biological processes<sup>87 88</sup> and DIMS technology may primarily influence the former. Both hypotheses warrant further investigation in dedicated patient groups.

Our findings also indicate that age significantly influences myopia progression, with younger patients exhibiting greater progression. This is in line with results obtained with DIMS lens use and the normal progression of myopia.<sup>69 81 83–85</sup> Additionally, we demonstrated that the rate of progression is similar in the first 6 and second 6 months in younger patients, in contrast to children aged 10 years and older, where it slows down after the first 6 months. Moreover, in our patient group, maternal myopia also emerged as an important factor for progression, especially in the case of severe maternal myopia. Interestingly, our pool of mothers demonstrated much higher incidence and severity of myopia compared with the fathers. It is possible that children with mothers with severe myopia having high dioptries are indeed more susceptible to myopia, but it is also plausible that mothers with myopia, being more aware and concerned,<sup>91</sup> may seek out new therapeutic options sooner. The significance of parental myopia is equivocal in the literature as it emerges as a predisposing factor in some studies,<sup>28 92–94</sup> whereas others do not find that it significantly affects progression<sup>69 81</sup> and was also shown to affect progression using single-vision and progressive-addition lenses differently.<sup>95</sup> Thus, this question merits further scrutiny.

Our study has some limitations, however. The limited availability of relevant literature on the effect of astigmatism on myopia progression makes it challenging to interpret the impact of astigmatism on DIMS therapy. One potential approach to address this issue is to reanalyse existing datasets on myopia progression using DIMS spectacles while considering astigmatism to evaluate its effect on progression. Another possible direction would be to explore newer lens designs in this context in a prospective study, comparing them with DIMS technology within a dedicated group of patients specifically selected for this purpose with careful consideration of astigmatism, age and parental myopia. In addition,

keratometric measurements alongside standard measurements would be valuable to better characterise the change in astigmatism.

Taken together, our results underline the importance of paying special attention to young children with myopic astigmatism, especially those with a family history of severe maternal myopia as our results suggest that in the European population, astigmatism, young age and severe maternal myopia are risk factors for suboptimal outcomes following DIMS therapy. Further research is necessary to elucidate the impact of astigmatism on myopic defocus therapy.

#### Author affiliations

<sup>1</sup>Non Plus Ultra Vision Centre, Budapest, Hungary

<sup>2</sup>Department of Ophthalmology, University of Pécs Medical School, Pécs, Hungary

<sup>3</sup>HUN-REN Research Centre for Natural Sciences, Budapest, Hungary

<sup>4</sup>Heim Pál National Pediatric Institute, Budapest, Hungary

<sup>5</sup>LIFE Leipzig Research Center for Civilization Diseases, Leipzig University, Leipzig, Germany

<sup>6</sup>Semmelweis University of Medicine, Budapest, Hungary

<sup>7</sup>Department of Ophthalmology, Semmelweis University of Medicine, Budapest, Hungary

**Acknowledgements** The authors thank Anett Bihari and Boglárka Nagy for patient contact and communication and for aiding in data collection.

**Contributors** PD, JK, ZZN and AC conceived the study. PD, JK and RS collected ophthalmological data. KL curated data. ÉMB and CM analysed data. ÉMB, PD and JK wrote the manuscript. AC and ZZN reviewed and ÉMB revised the manuscript. PD acted as guarantor. All authors read and approved the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. However, patients gave structured feedback on the new therapy. Refer to the Methods section for further details.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by the Medical Research Council of Hungary under the file number BM/27036-3/2023. Participants gave informed consent to participate in the study before taking part. The study conformed to the Declaration of Helsinki.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Deidentified participant data are available on reasonable request from PD (domsa.patricia@npumail.hu). Data reuse is only permitted with permission from PD.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Éva M Bankó <http://orcid.org/0009-0001-5354-5077>



## REFERENCES

- Williams KM, Verhoeven VJM, Cumberland P, *et al.* Prevalence of refractive error in Europe: the European eye epidemiology (E(3)) consortium. *Eur J Epidemiol* 2015;30:305–15.
- Grzybowski A, Kanclerz P, Tsubota K, *et al.* A review on the epidemiology of myopia in school children worldwide. *BMC Ophthalmol* 2020;20:27.
- Holden BA, Fricke TR, Wilson DA, *et al.* Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. *Ophthalmology* 2016;123:1036–42.
- Németh J, Daiki T, Dankovics G, *et al.* Prevalence of refractive errors in Hungary reveals three-fold increase in myopia. *Int J Ophthalmol* 2022;15:1174–9.
- Verhoeven VJM, Buitendijk GHS, Rivadeneira F, *et al.* Education influences the role of genetics in myopia. *Eur J Epidemiol* 2013;28:973–80.
- Hysi PG, Choquet H, Khawaja AP, *et al.* Meta-analysis of 542,934 subjects of European ancestry identifies new genes and mechanisms predisposing to refractive error and myopia. *Nat Genet* 2020;52:401–7.
- Saw S-M, Gazzard G, Shih-Yen EC, *et al.* Myopia and associated pathological complications. *Ophthalmic Physiol Opt* 2005;25:381–91.
- Haarman AEG, Enthoven CA, Tideman JW, *et al.* The complications of myopia: a review and meta-analysis. *Invest Ophthalmol Vis Sci* 2020;61:49.
- Chung K, Mohidin N, O'Leary DJ. Undercorrection of myopia enhances rather than inhibits myopia progression. *Vision Res* 2002;42:2555–9.
- Walline JJ, Lindsley K, Vedula SS, *et al.* Interventions to slow progression of myopia in children. *Cochrane Database Syst Rev* 2011:CD004916.
- Adler D, Millodot M. The possible effect of undercorrection on myopic progression in children. *Clin Exp Optom* 2006;89:315–21.
- Wildsoet CF, Chia A, Cho P, *et al.* IMI - interventions myopia Institute: interventions for controlling myopia onset and progression report. *Invest Ophthalmol Vis Sci* 2019;60:M106–31.
- Logan NS, Wolffsohn JS. Role of UN-correction, under-correction and over-correction of myopia as a strategy for slowing myopic progression. *Clin Exp Optom* 2020;103:133–7.
- Fulk GW, Cyert LA, Parker DE. A randomized trial of the effect of single-vision vs. bifocal lenses on myopia progression in children with esophoria. *Optom Vis Sci* 2000;77:395–401.
- Cheng D, Woo GC, Drobe B, *et al.* Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. *JAMA Ophthalmol* 2014;132:258–64.
- Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive-addition lenses versus single-vision lenses for slowing progression of myopia in children with high accommodative lag and near esophoria. *Invest Ophthalmol Vis Sci* 2011;52:2749–57.
- Yang Z, Lan W, Ge J, *et al.* The effectiveness of progressive addition lenses on the progression of myopia in Chinese children. *Ophthalmic Physiol Opt* 2009;29:41–8.
- Hasebe S, Ohtsuki H, Nonaka T, *et al.* Effect of progressive addition lenses on myopia progression in Japanese children: a prospective, randomized, double-masked, crossover trial. *Invest Ophthalmol Vis Sci* 2008;49:2781–9.
- Berntsen DA, Sinnott LT, Mutti DO, *et al.* A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation. *Invest Ophthalmol Vis Sci* 2012;53:640–9.
- Leung JT, Brown B. Progression of myopia in Hong Kong Chinese schoolchildren is slowed by wearing progressive lenses. *Optom Vis Sci* 1999;76:346–54.
- Gwiazda J, Hyman L, Hussein M, *et al.* A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. *Investigative Ophthalmology & Visual Science* 2003;44:1492–500.
- Walline JJ, Jones LA, Sinnott L, *et al.* A randomized trial of the effect of soft contact lenses on myopia progression in children. *Invest Ophthalmol Vis Sci* 2008;49:4702–6.
- Walline JJ, Jones LA, Mutti DO, *et al.* A randomized trial of the effects of rigid contact lenses on myopia progression. *Arch Ophthalmol* 2004;122:1760–6.
- Marsh-Tootle WL, Dong LM, Hyman L, *et al.* Myopia progression in children wearing spectacles versus switching to contact lenses. *Optom Vis Sci* 2009;86:741–7.
- Katz J, Schein OD, Levy B, *et al.* A randomized trial of rigid gas permeable contact lenses to reduce progression of children's myopia. *Am J Ophthalmol* 2003;136:82–90.
- Perrigin J, Perrigin D, Quintero S, *et al.* Silicone-acrylate contact lenses for myopia control: 3-year results. *Optom Vis Sci* 1990;67:764–9.
- Horner DG, Soni PS, Salmon TO, *et al.* Myopia progression in adolescent wearers of soft contact lenses and spectacles. *Optom Vis Sci* 1999;76:474–9.
- Jones LA, Sinnott LT, Mutti DO, *et al.* Parental history of myopia, sports and outdoor activities, and future myopia. *Invest Ophthalmol Vis Sci* 2007;48:3524–32.
- Rose KA, Morgan IG, Ip J, *et al.* Outdoor activity reduces the prevalence of myopia in children. *Ophthalmology* 2008;115:1279–85.
- Xiong S, Sankaridurg P, Naduvilath T, *et al.* Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. *Acta Ophthalmol* 2017;95:551–66.
- Cao K, Wan Y, Yusufu M, *et al.* Significance of outdoor time for myopia prevention: a systematic review and meta-analysis based on randomized controlled trials. *Ophthalmic Res* 2020;63:97–105.
- Wang J, Li Y, Musch DC, *et al.* Progression of myopia in school-aged children after COVID-19 home confinement. *JAMA Ophthalmol* 2021;139:293–300.
- Hu Y, Zhao F, Ding X, *et al.* Rates of myopia development in young Chinese schoolchildren during the outbreak of COVID-19. *JAMA Ophthalmol* 2021;139:1115–21.
- Ma M, Xiong S, Zhao S, *et al.* COVID-19 home quarantine accelerated the progression of myopia in children aged 7 to 12 years in China. *Invest Ophthalmol Vis Sci* 2021;62:37.
- Wen L, Cao Y, Cheng Q, *et al.* Objectively measured near work, outdoor exposure and myopia in children. *Br J Ophthalmol* 2020;104:1542–7.
- Huang H-M, Chang DS-T, Wu P-C. The association between near work activities and myopia in children-A systematic review and meta-analysis. *PLoS One* 2015;10:e0140419.
- Foreman J, Salim AT, Praveen A, *et al.* Association between digital smart device use and myopia: a systematic review and meta-analysis. *Lancet Digit Health* 2021;3:e806–18.
- He A-Q, Liu S-A, He S-Y, *et al.* Investigation of children's habits of smartphone usage and parental awareness of myopia control in underdeveloped areas of China. *Int J Ophthalmol* 2022;15:1691–8.
- Lam CS, Tang WC, Lee PH, *et al.* Myopia control effect of Defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. *Br J Ophthalmol* 2022;106:1110–4.
- Zhang H, Lam CSY, Tang W-C, *et al.* Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus incorporated multiple segments (DIMS) spectacle lenses. *J Clin Med* 2022;11:2294.
- Kaymak H, Neller K, Schütz S, *et al.* Vision tests on spectacle lenses and contact lenses for optical myopia correction: a pilot study. *BMJ Open Ophthalmol* 2022;7:e000971.
- Carlà MM, Boselli F, Giannuzzi F, *et al.* Overview on Defocus incorporated multiple segments lenses: a novel perspective in myopia progression management. *Vision* 2022;6:20.
- Lu Y, Lin Z, Wen L, *et al.* The adaptation and acceptance of Defocus incorporated multiple segment lens for Chinese children. *Am J Ophthalmol* 2020;211:207–16.
- Lam CSY, Tang WC, Tse DY-Y, *et al.* Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. *Br J Ophthalmol* 2020;104:363–8.
- Bao J, Huang Y, Li X, *et al.* Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. *JAMA Ophthalmol* 2022;140:472–8.
- Gao Y, Lim EW, Yang A, *et al.* The impact of spectacle lenses for myopia control on visual functions. *Ophthalmic Physiol Opt* 2021;41:1320–31.
- Bao J, Yang A, Huang Y, *et al.* One-year myopia control efficacy of spectacle lenses with Aspherical Lenslets. *Br J Ophthalmol* 2022;106:1171–6.
- Anstice NS, Phillips JR. Effect of dual-focus soft contact lens wear on axial myopia progression in children. *Ophthalmology* 2011;118:1152–61.
- Li S-M, Kang M-T, Wu S-S, *et al.* Studies using concentric ring bifocal and peripheral add multifocal contact lenses to slow myopia progression in school-aged children: a meta-analysis. *Ophthalmic Physiol Opt* 2017;37:51–9.
- Pauné J, Thivent S, Armengol J, *et al.* Changes in peripheral refraction, higher-order aberrations, and accommodative lag with a radial refractive gradient contact lens in young Myopes. *Eye Contact Lens* 2016;42:380–7.

- 51 Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-year randomized clinical trial of Misight lenses for myopia control. *Optom Vis Sci* 2019;96:556–67.
- 52 Chamberlain P, Bradley A, Arumugam B, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: a 6-year multicenter clinical trial. *Optom Vis Sci* 2022;99:204–12.
- 53 Sankaridurg P, Bakaraju RC, Naduvilath T, et al. Myopia control with novel central and peripheral plus contact lenses and extended depth of focus contact lenses: 2 year results from a randomised clinical trial. *Ophthalmic Physiol Opt* 2019;39:294–307.
- 54 Walline JJ, Walker MK, Mutti DO, et al. Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. *JAMA* 2020;324:571–80.
- 55 Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. *Br J Ophthalmol* 2009;93:1181–5.
- 56 Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. *Invest Ophthalmol Vis Sci* 2011;52:2170–4.
- 57 Cho P, Cheung S-W. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. *Invest Ophthalmol Vis Sci* 2012;53:7077–85.
- 58 Hiraoka T, Kakita T, Okamoto F, et al. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. *Invest Ophthalmol Vis Sci* 2012;53:3913–9.
- 59 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, et al. Myopia control with Orthokeratology contact lenses in Spain: refractive and biometric changes. *Invest Ophthalmol Vis Sci* 2012;53:5060–5.
- 60 Chua W-H, Balakrishnan V, Chan Y-H, et al. Atropine for the treatment of childhood myopia. *Ophthalmology* 2006;113:2285–91.
- 61 Chia A, Chua W-H, Cheung Y-B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). *Ophthalmology* 2012;119:347–54.
- 62 Tong L, Huang XL, Koh ALT, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. *Ophthalmology* 2009;116:572–9.
- 63 Chia A, Lu Q-S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. *Ophthalmology* 2016;123:391–9.
- 64 Bullimore MA, Berntsen DA. Low-dose atropine for myopia control: considering all the data. *JAMA Ophthalmol* 2018;136:303.
- 65 Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. *Ophthalmology* 2019;126:113–24.
- 66 Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. *Ophthalmology* 2020;127:910–9.
- 67 Yam JC, Zhang XJ, Zhang Y, et al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus Washout: phase 3 report. *Ophthalmology* 2022;129:308–21.
- 68 Bullimore MA, Richdale K. Myopia control 2020: where are we and where are we heading. *Ophthalmic Physiol Opt* 2020;40:254–70.
- 69 Lam CSY, Tang WC, Qi H, et al. Effect of Defocus incorporated multiple segments spectacle lens wear on visual function in myopic Chinese children. *Transl Vis Sci Technol* 2020;9:11.
- 70 Lam CSY, Tang WC, Zhang HY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. *Sci Rep* 2023;13:5475.
- 71 Jaskulski M, Singh NK, Bradley A, et al. Optical and imaging properties of a novel multi-segment spectacle lens designed to slow myopia progression. *Ophthalmic Physiol Opt* 2020;40:549–56.
- 72 Nucci P, Lembo A, Schiavetti I, et al. A comparison of myopia control in European children and adolescents with Defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. *PLoS One* 2023;18:e0281816.
- 73 Truckenbrod C, Meigen C, Brandt M, et al. Longitudinal analysis of axial length growth in a German cohort of healthy children and adolescents. *Ophthalmic Physiol Opt* 2021;41:532–40.
- 74 Liu J, Lu Y, Huang D, et al. The efficacy of Defocus incorporated multiple segments lenses in slowing myopia progression: results from diverse clinical circumstances. *Ophthalmology* 2023;130:542–50.
- 75 Long E. Evolutionary medicine: why does prevalence of myopia significantly increase. *Evol Med Public Health* 2018;2018:151–2.
- 76 von Elm E, Altman DG, Egger M, et al. The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453–7.
- 77 Verkicharla PK, Thakur S, Kekunnaya R, et al. The IMPACT myopia management guidelines. *Indian J Ophthalmol* 2023;71:2882–4.
- 78 Long WF. A matrix formalism for decentration problems. *Am J Optom Physiol Opt* 1976;53:27–33.
- 79 Kaye SB, Rubin A, Evans T, et al. Standardised approach to the reporting and presentation of refractive data: electronic patient record. *BMJ Open Ophthalmol* 2022;7:e001015.
- 80 Keating MP. On the use of matrices for the mean value of refractive errors. *Ophthalmic Physiol Opt* 1983;3:201–3.
- 81 Jones-Jordan LA, Sinnott LT, Chu RH, et al. Myopia progression as a function of sex, age, and ethnicity. *Invest Ophthalmol Vis Sci* 2021;62:36.
- 82 Kaymak H, Mattern A-I, Graff B, et al. Safety of DIMS spectacle lenses and atropine as combination therapy for myopia progression. *Klin Monbl Augenheilkd* 2022;239:1197–205.
- 83 Verkicharla PK, Kammari P, Das AV. Myopia progression varies with age and severity of myopia. *PLoS One* 2020;15:e0241759.
- 84 Tricard D, Marillet S, Ingrand P, et al. Progression of myopia in children and teenagers: a nationwide longitudinal study. *Br J Ophthalmol* 2022;106:1104–9.
- 85 Qin Z, Peng T, Zhang Z, et al. Myopia progression and stabilization in school-aged children with single-vision lenses. *Acta Ophthalmol* 2022;100:e950–6.
- 86 Vyas SA, Kee C-S. Early astigmatism can alter myopia development in chickens. *Invest Ophthalmol Vis Sci* 2021;62:27.
- 87 Shih YF, Ho TC, Chen MS, et al. Experimental myopia in chickens induced by corneal astigmatism. *Acta Ophthalmol (Copenh)* 1994;72:597–601.
- 88 Kee C-S, Deng L. Astigmatism associated with experimentally induced myopia or hyperopia in chickens. *Invest Ophthalmol Vis Sci* 2008;49:858–67.
- 89 Hoseini-Yazdi H, Vincent SJ, Read SA, et al. Astigmatic Defocus leads to short-term changes in human choroidal thickness. *Invest Ophthalmol Vis Sci* 2020;61:48.
- 90 Bankó ÉM, Barboni MTS, Markó K, et al. Fixation instability, astigmatism, and lack of stereopsis as factors impeding recovery of binocular balance in amblyopia following binocular therapy. *Sci Rep* 2022;12:10311.
- 91 Ortiz-Peregrina S, Solano-Molina S, Martino F, et al. Parental awareness of the implications of myopia and strategies to control its progression: a survey-based study. *Ophthalmic Physiol Opt* 2023;43:1145–59.
- 92 Pärssinen O, Hemminki E, Klemetti A. Effect of spectacle use and accommodation on myopic progression: final results of a three-year randomised clinical trial among schoolchildren. *Br J Ophthalmol* 1989;73:547–51.
- 93 Lee SS-Y, Mackey DA. Prevalence and risk factors of myopia in young adults: review of findings from the Raine study. *Front Public Health* 2022;10:861044.
- 94 Liao C, Ding X, Han X, et al. Role of parental refractive status in myopia progression: 12-year annual observation from the Guangzhou twin eye study. *Invest Ophthalmol Vis Sci* 2019;60:3499–506.
- 95 Kurtz D, Hyman L, Gwiazda JE, et al. Role of parental myopia in the progression of myopia and its interaction with treatment in COMET children. *Invest Ophthalmol Vis Sci* 2007;48:562–70.